U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

Lipophilic-polycationic delivery systems

Patent 6005004 Issued on December 21, 1999. Estimated Expiration Date: Icon_subject December 21, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Patent References

Novel functionallized liposomes and a process for production thereof
Patent #: 4861597
Issued on: 08/29/1989
Inventor: Kida ,   et al.

Methods of treating Parkinson's disease using melanin
Patent #: 5210076
Issued on: 05/11/1993
Inventor: Berliner, et al.

Microreservoir liposome composition and method
Patent #: 5225212
Issued on: 07/06/1993
Inventor: Martin, et al.

Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
Patent #: 5433946
Issued on: 07/18/1995
Inventor: Allen, Jr., et al.

Phospholipids containing omega-3-fatty acids
Patent #: 5434183
Issued on: 07/18/1995
Inventor: Larsson-Backstrom

Deposition of materials to surfaces using zwitterionic carrier particles
Patent #: 5476660
Issued on: 12/19/1995
Inventor: Somasundaran, et al.

Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents Patent #: 5604198
Issued on: 02/18/1997
Inventor: Poduslo, et al.

Inventors

Assignee

Application

No. 487693 filed on 06/07/1995

US Classes:

514/549, Z radical contains carbon to carbon unsaturation514/552, Z contains an unbroken chain of at least seven carbon atoms bonded directly to the C(=O) group514/558, Higher fatty acid or salt thereof514/560Carbon to carbon unsaturation

Examiners

Primary: Smith, Lynette R. F.
Assistant: Lee, Datquan

Attorney, Agent or Firm

International Classes

A01N 037/06
A01N 037/02
A61K 031/22
A61K 031/23

Abstract

The present invention describes site-specific biomolecular complexes comprising a therapeutic, prophylactic and diagnostic agent, called also biologically active molecule and an omega-3 fatty acid and derivatives thereof. The complexes are further covalently bonded with cationic carriers and permeabilizer peptides for delivery across the blood-brain barrier and with targeting moieties for uptake by target brain cells. Said complexes are particularly useful for delivery of a biologically active agent to the glial tissue of the brain as well as to the cortical, cholinergic and adrenergic neurons. The preferred therapeutic complexes or conjugates comprise an omega-3 fatty acid such as alpha-linolenic acid, eicosapentaenoic acid or docosahexaenoic acid and derivatives thereof.

Other References

  • Frenkel. "Gaucher disease: a heterogenous clinical complex for which effective enzyme replacement has come of age". American Journal of the Medical Sciences. vol.305, No.5, pp. 331-344, May 199
PatentsPlus Images
Enhanced PDF formats
loading...
PatentsPlus: add to cart
PatentsPlus: add to cartSearch-enhanced full patent PDF image
$9.95more info
PatentsPlus: add to cart
PatentsPlus: add to cartIntelligent turbocharged patent PDFs with marked up images
$18.95more info
 
Sign InRegister
Username  
Password   
forgot password?